There is no other way to characterize Insulet’s results as they are flat out killing it. Check out these facts from the press release;
“Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year, exceeds guidance of $174 to $181 million
For the year ending December 31, 2019, the Company is raising its revenue guidance to a range of $722 to $730 million, representing growth of 28% to 29% (previously 24% to 27%). Revenue ranges by product line are:
• U.S. Omnipod of $410 to $414 million . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.